THIRTEEN WEEK ORAL TOXICITY STUDY OF P-XSC IN DOGS

癌症预防与治疗部化学预防分支 国家癌症研究所的控制指导了一个项目， 开发人类使用的药物，以预防，延迟或逆转 细胞发育不良（例如上皮内瘤变）进展至 侵袭性癌症 药物研发过程的一部分 涉及临床前毒理学研究。 进行这些研究 根据已发布的指南文件，遵循药物非临床研究质量管理规范 由食品和药物管理局，并用于支持 研究性新药申请和最终新药申请 癌症化学预防剂的上市许可。 承包商应进行为期13周的1，4- 犬中的亚苯基双（亚甲基）硒氰酸酯。 在以前的一项研究中， 观察到这种复合性血小板减少症。 本研究旨在 评估这种影响的机制，并测试假设，它 是基于药物诱导的免疫反应

The Chemoprevention Branch of the Division of Cancer Prevention and Control at the National Caner Institute directs a program to identify and develop drugs for human use that will prevent, delay, or reverse the progression of cellular dysplasia (e.g. intraepithelial neoplasia) to invasive cancer. part of the drug research and development process involves preclinical toxicology studies. These studies are performed under Good Laboratory Practices according to guidance documents published by the Food and Drug Administration and are used to support Investigational New Drug applications and eventually New Drug Applications to the marketing approval of cancer chemopreventive agents. The contractor shall conduct a 13-week toxicity study of 1,4- Phenylenebis(methylene) selenocyanate in dogs. In a previous study of this compound thrombocytopenia was observed. This study is designed to evaluate the mechanism of this effect and to test the hypothesis that it is based on a drug-induced immune response.